Evotec (NASDAQ:EVO) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Evotec (NASDAQ:EVO – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

View Our Latest Analysis on EVO

Evotec Price Performance

Shares of Evotec stock opened at $3.76 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48. Evotec has a 12 month low of $2.84 and a 12 month high of $4.80. The business has a fifty day simple moving average of $3.16 and a 200 day simple moving average of $3.61.

Hedge Funds Weigh In On Evotec

Several institutional investors and hedge funds have recently modified their holdings of EVO. Valeo Financial Advisors LLC acquired a new position in Evotec in the 2nd quarter worth $43,000. BNP Paribas Financial Markets raised its stake in shares of Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the period. Thrivent Financial for Lutherans bought a new stake in shares of Evotec in the third quarter valued at about $53,000. Bank of America Corp DE boosted its position in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. Finally, UMB Bank n.a. bought a new position in shares of Evotec during the second quarter worth about $56,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

(Get Free Report)

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

Further Reading